18 Participants Needed

Novel Combination Therapy for B-Cell Lymphoma

Recruiting at 4 trial locations
AH
LS
Overseen ByLois Shepherd
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications. However, certain treatments like biologic agents and radiation are not allowed within 28 days before enrollment, and steroids should be avoided 7 days prior unless necessary. It's best to discuss your specific medications with the trial team.

What data supports the effectiveness of the drug combination therapy for B-cell lymphoma?

Rituximab, a key component of the combination therapy, has been shown to significantly improve outcomes in B-cell lymphomas like diffuse large B-cell lymphoma and follicular lymphoma when added to chemotherapy. Studies have demonstrated that rituximab enhances response rates, progression-free survival, and overall survival in these conditions.12345

Is the novel combination therapy for B-cell lymphoma safe for humans?

The combination therapy involving Venetoclax and Rituximab has been shown to have a manageable safety profile in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Common side effects include blood-related issues like neutropenia (low white blood cell count), but these are generally manageable with proper care.678910

What makes the novel combination therapy for B-cell lymphoma unique?

This novel combination therapy for B-cell lymphoma is unique because it combines multiple drugs, including rituximab and venetoclax, which target cancer cells in different ways. Rituximab is a monoclonal antibody that targets the CD20 protein on B-cells, while venetoclax helps induce cancer cell death by inhibiting a protein called BCL-2. This multi-faceted approach may enhance treatment effectiveness compared to standard therapies.511121314

What is the purpose of this trial?

The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects. The study treatment is new agents in combination with R-GDP or an equivalent regimen.

Research Team

SA

Sarit Assouline

Principal Investigator

The Jewish General Hospital, Montreal QC, Canada

DV

Diego Villa

Principal Investigator

BCCA - Vancouver Cancer Centre, BC, Canada

TB

Tara Baetz

Principal Investigator

Cancer Centre of Southeastern Ontario at Kingston, ON, Canada

Eligibility Criteria

This trial is for adults under 65 with aggressive B-cell lymphoma that's come back or didn't respond to first treatments. They must be fit enough for intensive chemo and a stem cell transplant, have measurable disease, and not have severe heart issues, uncontrolled infections, or other cancers being treated. Women who can get pregnant and men must agree to contraception.

Inclusion Criteria

I have been diagnosed with a specific type of lymphoma or my previous lymphoma has transformed into a more aggressive form.
In accordance with CCTG policy, protocol treatment is to begin within 5 working days of patient enrollment.
AST and ALT ≤ 3x ULN
See 15 more

Exclusion Criteria

I have had a serious stomach or intestinal bleed in the last month.
I have not received any live vaccines in the last 4 weeks.
I have not started any new treatments in the last two weeks.
See 16 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive increasing doses of the new drug in combination with R-GDP to determine the highest tolerable dose without severe side effects

8-12 weeks

Treatment

Participants receive the new drug in combination with R-GDP at the determined dose

6 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Cisplatin
  • Dexamethasone
  • Gemcitabine
  • RiTUXimab Injection
  • Rituximab SC
  • Venetoclax
Trial Overview The study tests new drug combinations alongside standard R-GDP chemotherapy (Rituximab, Gemcitabine, Dexamethasone, Cisplatin) or similar regimens in patients whose lymphoma has returned or resisted treatment. It aims to find the highest safe dose of these new combos without causing very severe side effects.
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Venetoclax + R-GDPExperimental Treatment6 Interventions
Group II: Tafasitamab + R-GDPExperimental Treatment1 Intervention
Group III: Glofitamab + R-GDPExperimental Treatment6 Interventions

Cisplatin is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Platinol for:
  • Testicular cancer
  • Ovarian cancer
  • Cervical cancer
  • Bladder cancer
  • Head and neck cancer
  • Esophageal cancer
  • Lung cancer
  • Mesothelioma
  • Brain tumors
  • Neuroblastoma
🇺🇸
Approved in United States as Platinol for:
  • Testicular cancer
  • Ovarian cancer
  • Cervical cancer
  • Bladder cancer
  • Head and neck cancer
  • Esophageal cancer
  • Lung cancer
  • Mesothelioma
  • Brain tumors
  • Neuroblastoma
🇨🇦
Approved in Canada as Platinol for:
  • Testicular cancer
  • Ovarian cancer
  • Cervical cancer
  • Bladder cancer
  • Head and neck cancer
  • Esophageal cancer
  • Lung cancer
  • Mesothelioma
  • Brain tumors
  • Neuroblastoma
🇯🇵
Approved in Japan as Platinol for:
  • Testicular cancer
  • Ovarian cancer
  • Cervical cancer
  • Bladder cancer
  • Head and neck cancer
  • Esophageal cancer
  • Lung cancer
  • Mesothelioma
  • Brain tumors
  • Neuroblastoma

Find a Clinic Near You

Who Is Running the Clinical Trial?

Canadian Cancer Trials Group

Lead Sponsor

Trials
135
Recruited
70,300+

Incyte Corporation

Industry Sponsor

Trials
408
Recruited
66,800+
Steven Stein profile image

Steven Stein

Incyte Corporation

Chief Medical Officer since 2015

MD from University of Witwatersrand

Hervé Hoppenot profile image

Hervé Hoppenot

Incyte Corporation

Chief Executive Officer since 2014

MBA from ESSEC Business School

Roche Pharma AG

Industry Sponsor

Trials
413
Recruited
430,000+
Dr. Thomas Schinecker profile image

Dr. Thomas Schinecker

Roche Pharma AG

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Dr. Levi Garraway profile image

Dr. Levi Garraway

Roche Pharma AG

Chief Medical Officer since 2019

MD from University of California, San Francisco

AbbVie

Industry Sponsor

Trials
1,079
Recruited
535,000+
Founded
2013
Headquarters
North Chicago, USA
Known For
Immunology treatments
Top Products
Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael profile image

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois

Findings from Research

Rituximab is the first monoclonal antibody approved for treating B-cell lymphomas, showing significant effectiveness in conditions like follicular lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma.
The combination of rituximab with standard chemotherapy agents (cyclophosphamide, doxorubicin, vincristine, and prednisone) has achieved the highest efficacy reported for treating diffuse large B-cell lymphoma and follicular lymphoma, while maintaining low toxicity.
Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.Traullé, C., Coiffier, BB.[2015]
The addition of rituximab, a monoclonal antibody, to conventional chemotherapy (R-CHOP regimen) significantly enhances treatment outcomes for patients with diffuse large B-cell lymphoma (DLBCL), improving response rates, progression-free survival (PFS), and overall survival (OS).
Rituximab also boosts response rates and PFS in mantle cell lymphoma (MCL) and improves outcomes in follicular lymphoma (FL), highlighting its critical role in enhancing the efficacy of chemotherapy across various types of non-Hodgkin's lymphoma.
Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma.Kahl, B.[2021]
Rituximab is a highly effective monoclonal antibody for treating various B-cell lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma, demonstrating a strong activity with low toxicity.
The combination of rituximab with chemotherapy (R-CHOP) has shown the highest efficacy reported for any chemotherapy regimen in treating diffuse large B-cell lymphoma and follicular lymphoma, although some patients may still be resistant to treatment.
Rituximab therapy in malignant lymphoma.Coiffier, B.[2022]

References

Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. [2015]
Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma. [2021]
Rituximab therapy in malignant lymphoma. [2022]
Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. [2017]
Use of rituximab, the new FDA-approved antibody. [2019]
Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia . [2018]
Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia. [2020]
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. [2021]
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia. [2022]
Novel CD20 monoclonal antibodies for lymphoma therapy. [2022]
Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL. [2015]
13.United Statespubmed.ncbi.nlm.nih.gov
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. [2022]
14.United Statespubmed.ncbi.nlm.nih.gov
The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security